CD274 and cancer: In response to these gaps in knowledge, the current study presents the results of a non-randomized phase 2 trial assessing the tolerance, efficacy, and immune correlates of SBRT and anti-PD-L1 atezolizumab association for patients with metastatic pretreated cancers,15 including STS.